IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Tsvetkova, et al.

Serial No.:

Not Assigned

Filed:

Herewith

For:

THERAPEUTIC PLATELETS AND

METHODS

Group Art Unit:

1633

Examiner:

Shin-Lin Chen

Attorney Docket:

6829/60490

CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. § 1.8(a))

I hereby certify that this correspondence is, on the date shown below is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" addressed to Box Patent Application, Commissioner for Patents, Washington, D.C. 20231.

August 232001

Iordan Wilson

PRELIMINARY AMENDMENT

BOX PATENT APPLICATION

Commissioner for Patents Washington, D.C. 20231

Sir:

Please enter the following Preliminary Amendment for the subject patent application:

IN THIS SPECIFICATION

Please enter the following sentence at page 1, line 8: --- This is a continuation patent application of copending patent application Serial No. 09/828,627, filed April 5, 2001. Patent application Serial No. 09/828,627 is a continuation patent application of patent application Serial No. 09/501,773, filed February 10, 2000. Benefit of all earlier filing dates is claimed.

IN THE CLAIMS

Please cancel Claims 1-32 without prejudice and add the following claims:

33. A process of preparing loaded platelets comprising:

providing platelets selected from a mammalian species; and loading an oligosaccharide into the platelets at a temperature greater than about 25°C to produce loaded platelets.

- 34. The process of Claim 33 wherein said loading comprises loading with an oligosaccharide solution.
- 35. The process of Claim 34 wherein said loading comprises uptaking external oligosaccharide via fluid phase endocytosis from the oligosaccharide solution at the temperature greater than about 25°C.
- 36. The process of Claim 34 wherein said loading comprises incubating the platelets at the temperature greater than about 25°C with the oligosaccharide solution.
 - 37. The process of Claim 33 wherein said loading is without a fixative.
 - 38. The process of Claim 33 wherein said oligosaccharide is trehalose.

- 47. The solution of Claim 44 wherein said oligosaccharide is trehalose.
- 48. The solution of Claim 44 wherein said temperature of said oligosaccharide ranges from a temperature greater than about 25°C to a temperature less than about 40°C.
- 49. The solution of Claim 48 wherein said temperature ranges from about 30°C to less than about 40°C.
 - 50. The solution of Claim 49 wherein said temperature is about 37°C.
 - 51. The solution of Claim 44 wherein said platelets are human platelets.
 - 52. The solution of Claim 49 wherein said platelets are human platelets.
- 53. A process for increasing the loading efficiency of trehalose into platelets comprising:

disposing the platelets into a trehalose solution for loading trehalose into the platelets; and

heating the trehalose solution to the second phase transition temperature range to increase the loading efficiency of trehalose into the platelets.

- 54. The process of Claim 53 additionally comprising uptaking external trehalose via fluid phase endocytosis from the trehalose solution.
 - 55. The process of Claim 53 wherein said platelets are human platelets.
- 56. The process of Claim 53 wherein said second phase transition temperature range is greater than about 25°C.
- 57. The process of Claim 55 wherein said second phase transition temperature range is greater than about 25°C.
 - 58. The process of Claim 53 wherein said platelets do not include a fixative.
 - 59. The process of Claim 55 wherein said platelets do not include a fixative.
- 60. The process of Claim 56 wherein said second phase transition temperature ranges from a temperature greater than about 25°C to a temperature less than about 40°C.
- 61. The process of Claim 55 wherein said second phase transition temperature ranges from a temperature greater than about 25°C to a temperature less than about 40°C.
- 62. The process of Claim 60 wherein said temperature ranges from about 30°C to less than about 40°C.

- 63. The process of Claim 61 wherein said temperature ranges from about 30°C to less than about 40°C.
- 64. A platelet composition comprising platelets loaded internally with an oligosaccharide from an oligosaccharide solution at a temperature greater than about 25°C.
- 65. A process for increasing the loading efficiency of a substance into platelets comprising:

disposing the platelets into a substance solution for loading a substance into the platelets; and

heating the substance solution to the second phase transition temperature range to increase the loading efficiency of the substance into the platelets.

- 66. The process of Claim 65 wherein said substance comprises a drug selected from a group of drugs consisting of an anti-thrombic drug, an antibiotic drug, and an anti-mitotic drug.
- 67. The process of Claim 66 wherein said anti-thrombic drug comprises a tissue plasminogen activator.
- 68. The process Claim 65 additionally comprising uptaking external substance via fluid phase endocytosis from the substance solution.
 - 69. The process of Claim 65 wherein said platelets are human platelets.

- 70. The process of Claim 65 wherein said second phase transition temperature range is greater than about 25°C.
 - 71. The process of Claim 65 wherein said platelets do not include a fixative.
- 72. The process of Claim 70 wherein said second phase transition temperature ranges from a temperature greater than about 25°C to a temperature less than about 40°C.
- 73. The process of Claim 72 wherein said temperature ranges from about 30°C to less than about 40°C.

Respectfully submitted,

higher 23,2001

ohn W. Carpenter

COUDERT BROTHERS 600 Beach Street, 3rd Floor San Francisco CA 94109 Telephone: 415/409-2900

Facsimile: 415/409-7400

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 1-32 have been cancelled.

The following claims have been added:

33. A process of preparing loaded platelets comprising:

providing platelets selected from a mammalian species; and

loading an oligosaccharide into the platelets at a temperature greater

than about 25°C to produce loaded platelets.

- 34. The process of Claim 33 wherein said loading comprises loading with an oligosaccharide solution.
- 35. The process of Claim 34 wherein said loading comprises uptaking external oligosaccharide via fluid phase endocytosis from the oligosaccharide solution at the temperature greater than about 25°C.
- 36. The process of Claim 34 wherein said loading comprises incubating the platelets at the temperature greater than about 25°C with the oligosaccharide solution.
 - 37. The process of Claim 33 wherein said loading is without a fixative.
 - 38. The process of Claim 33 wherein said oligosaccharide is trehalose.

- 39. The process of Claim 33 wherein said loading of the oligosaccharide into the platelets is at a temperature ranging from greater than about 25°C to less than about 40°C.
- 40. The process of Claim 39 wherein said temperature ranges from about 30°C to less than about 40°C.
 - 41. The process of Claim 39 wherein said temperature is about 37°C.
 - 42. The process of Claim 33 wherein said platelets are human platelets.
- 43. Loaded platelets produced in accordance with the process of Claim 33.
- 44. A solution for loading platelets comprising platelets selected from a mammalian species; and an oligosaccharide solution containing the platelets and a temperature greater than about 25°C for loading oligosaccharide from the oligosaccharide solution into the platelets.
- 45. The solution of Claim 44 wherein external oligosaccharide is uptaked via fluid phase endocytosis from the oligosaccharide solution at the temperature greater than about 25°C.
 - 46. The solution of Claim 44 wherein said solution does not include a fixative.

- 47. The solution of Claim 44 wherein said oligosaccharide is trehalose.
- 48. The solution of Claim 44 wherein said temperature of said oligosaccharide ranges from a temperature greater than about 25°C to a temperature less than about 40°C.
- 49. The solution of Claim 48 wherein said temperature ranges from about 30°C to less than about 40°C.
 - 50. The solution of Claim 49 wherein said temperature is about 37°C.
 - 51. The solution of Claim 44 wherein said platelets are human platelets.
 - 52. The solution of Claim 49 wherein said platelets are human platelets.
- 53. A process for increasing the loading efficiency of trehalose into platelets comprising:

disposing the platelets into a trehalose solution for loading trehalose into the platelets; and

heating the trehalose solution to the second phase transition temperature range to increase the loading efficiency of trehalose into the platelets.

- 54. The process of Claim 53 additionally comprising uptaking external trehalose via fluid phase endocytosis from the trehalose solution.
 - 55. The process of Claim 53 wherein said platelets are human platelets.
- 56. The process of Claim 53 wherein said second phase transition temperature range is greater than about 25°C.
- 57. The process of Claim 55 wherein said second phase transition temperature range is greater than about 25°C.
 - 58. The process of Claim 53 wherein said platelets do not include a fixative.
 - 59. The process of Claim 55 wherein said platelets do not include a fixative.
- 60. The process of Claim 56 wherein said second phase transition temperature ranges from a temperature greater than about 25°C to a temperature less than about 40°C.
- 61. The process of Claim 55 wherein said second phase transition temperature ranges from a temperature greater than about 25°C to a temperature less than about 40°C.

- 62. The process of Claim 60 wherein said temperature ranges from about 30°C to less than about 40°C.
- 63. The process of Claim 61 wherein said temperature ranges from about 30°C to less than about 40°C.
- 64. A platelet composition comprising platelets loaded internally with an oligosaccharide from an oligosaccharide solution at a temperature greater than about 25°C.
- 65. A process for increasing the loading efficiency of a substance into platelets comprising:

disposing the platelets into a substance solution for loading a substance into the platelets; and

heating the substance solution to the second phase transition temperature range to increase the loading efficiency of the substance into the platelets.

66. The process of Claim 65 wherein said substance comprises a drug selected from a group of drugs consisting of an anti-thrombic drug, an antibiotic drug, and an anti-mitotic drug.

- 67. The process of Claim 66 wherein said anti-thrombic drug comprises a tissue plasminogen activator.
- 68. The process Claim 65 additionally comprising uptaking external substance via fluid phase endocytosis from the substance solution.
 - 69. The process of Claim 65 wherein said platelets are human platelets.
- 70. The process of Claim 65 wherein said second phase transition temperature range is greater than about 25°C.
 - 71. The process of Claim 65 wherein said platelets do not include a fixative.
- 72. The process of Claim 70 wherein said second phase transition temperature ranges from a temperature greater than about 25°C to a temperature less than about 40°C.
- 73. The process of Claim 72 wherein said temperature ranges from about 30° C to less than about 40° C.